JC17 Rec'd PCT/PTO 24 MAR 2005

MODIFIED P.TO/SB/08 (08-00)
Approved e through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark
U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

HUITIDET.					
	Substitute for form 1449B/PTO INFORMATION DISCLOSURE				Complete if Known of # 50011
				Int. Application Number	PCT/GB03/04218
STATEMENT BY APPLICANT			CANT	Int. Appl. Filing Date	09/29/2003
				First Named Inventor	Ralph BRAUN
			•	Group Art Unit	Unaccigned 1632
	(use as many sheets as necessary)			Examiner Name	Unassigned /Wu-Cheng Winston Shen/
Sheet	1	of	1	Attorney Docket Number	036481-0165

			,	U.S. PATENT DOCUMENTS	3	⊹ ;
Examiner Initials*		U.S. Patent	Document	Name of Patentee or Applicant of Cited Document	Date of Publication of	Pages; Columns, Lines, Where Relevant
	Cite No. ¹	Number	Kind Code ² (if known)		Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
/W.S./	A1	5,162,222	А	Linda GUARINO et al.	11-10-1992	
				,		

			. F(DREIGN PATENT DOCUMEN	TS		
Cite No. ¹				Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
A2	FR	2 715 664	А	PROTEINE PERFORMANCE SA	08-04-1995		
А3	wo	98/30707	A	UNIV LONDON et al.	07-16-1998		<u> </u>
	No.1	No.1 Office A2 FR	No. 1 Office 3 Number 4 A2 FR 2 715 664	Cite No.1 Foreign Patent Document Office3 Number4 Kind Code5 (if known) A2 FR 2 715 664 A	Cite No. 1 Foreign Patent Document Name of Patentee or Applicant of Cited Documents A2 FR 2 715 664 A PROTEINE PERFORMANCE SA	Cite No. 1 Foreign Patent Document Name of Patentee or Applicant of Cited Document MM-DD-YYYY A2 FR 2 715 664 A PROTEINE PERFORMANCE SA Date of Publication of Cited Documents MM-DD-YYYY PROTEINE PERFORMANCE SA 08-04-1995	Cite No.1 Office3 Number4 Kind Code5 (if known) Name of Patentee or Applicant of Cited Documents MM-DD-YYYY Passages or Relevant Figures Appear A2 FR 2715 664 A PROTEINE PERFORMANCE SA 08-04-1995

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
/W.S./	À4	VAN DRUNEN et al., "Immunization of livestock with DNA vaccines: current studies and future prospects," Vaccine , March 21, 2001, pp. 2474-2479, Vol. 19, No. 17-19, Butterworth Scientific, Guildford, GB	

Examiner Signature	/Wu-Cheng Winston Shen/	Date Considered	04/02/2007
Olgitatore		Considered	0 1/02/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE der the Paperwark Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

O NO PROSTITUTE FOR THE PROSTITUTE OF T

ate Submitted: February 20, 2007

of_

(use as many sheets as necessary)

Sheet

Complete if Known					
Application Number	10/529,011				
Filing Date	9/29/2003				
First Named Inventor	Raiph BRAUN				
Art Unit	1632				
Examiner Name	Shen, Wu Cheng Winston				
Attorney Docket Number	036481-0165				

	U.S. PATENT DOCUMENTS						
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant		
Initials*	No.1	Number-Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear		
/W.S./	A1	US-5,057,540	10-15-1991	Kensil et al.			
/W.S./	A2	US-5,171,568	12-15-1992	Burke et al.			
/W.S./	A3	US-5,328,688	07-12-1994	Roizman			
WS/	A4	US-5,378,814	01-03-1995	Houghton et al.			
/W.S./	A5	US-5,865,796	02-02-1999	McCabe			
_/W.S./	A6	US-5,922,576	07-13-1999	He et al.			
	l						

		UNPUBLISH	IED U.S. PATENT APP	PLICATION DOCUMENTS	
Examiner Initials*	Cite No. ¹	U.S. Patent Application Document Serial Number-Kind Code ² (if known)	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

			FOREIGN PATENT	DOCUMENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
/W.S./	A7	WO 89/04669	06-01-1989	Chiron Corporation		
./W.S./	A8	WO 90/11089	10-04-1990	Chiron Corporation		T
WS/	A9	WO 90/14436	11-29-1990	Chiron Corporation		1
W.S./	A10	WO 92/16636	10-01-1992	Immunology Limited		T
WS/	A11	WO 93/18759	09-30-1993	Bayor College of Medicine		
/W.S./	A12	WO 93/19768	10-14-1993	The Regents of the Univ. of California		
/W.S./	A13	WO 94/12202	06-09-1994	University of Dundee		1.
/W.S./	A14	WO 96/29421	09-26-1996	Cantab Pharmaceuticals Research Limited		
/W.S./	A15	WO 96/40955	12-19-1996	Frank L. GRAHAM		T
/W.S./	A16	WO 98/21345	05-22-1998	The General Hospital Corporation		
.W.S./	A17	WO 01/32221 A1	05-10-2001	Powderject Vaccines, Inc.		1
/W.S./	A18	WO 01/46449 A1	06-28-2001	Biovex Limited		T

			, , , , , , , , , , , , , , , , , , ,
Examiner Signature	/Wu-Cheng Winston Shen/	Date Considered	04/02/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for form 1449/PTO				Complete if Known		
	INFORMATI	ON DISCLO	SURE	Application Number	10/529,011		
STATEMENT BY APPLICANT			ICANT	Filing Date	9/29/2003		
	Date Submitted: February 20, 2007			First Named Inventor	Ralph BRAUN		
	Date Submitte	u. reblualy	20, 2007	Art Unit	1632		
<u> </u>	(use as many	sheets as ne	ecessary)	Examiner Name	Shen, Wu Cheng Winston		
Sheet	2	of	4	Attorney Docket Number	036481-0165		

			FOREIGN PATENT	DOCUMENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ°
/W.S./	A19	WO 01/46450 A1	06-28-2001	Biovex Limited		I
					·	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T⁵	
/W.S./	W.S./ BAER, R., et al., "DNA Sequence and Expression of the B95-8 Epstein-Barr Virus Genome", <i>Nature</i> , July 19, 1984, Vol. 310, pp. 207-211.			
/W.S./	A21	BIXLER et al., "Synthetic Peptide Representing a T-Cell Epitope of CRM197 Substitutes as Carrier Molecule in a Haemophilus Influenzae Type B (HIB) Conjugate Vaccine", <i>Adv. Exp. Med. Biol.</i> , (1989), Vol. 251, pp. 175-180.		
/W.S./	A22	CHEE, M.S., et al., "Analysis of the Protein-Coding Content of the Sequence of Human Cytomegalovirus Strain AD169", <i>Current Topics in Microbiology and Immunology</i> , (1990), Vol. 154, pp. 125-169.		
/W.S./	A23	COFFIN, R.S., et al., "Herpes Simplex Virus-Based Vectors – Genetic Manipulation of the Nervous System", <i>Academic Press Limited</i> , (1996), ISBN 0-12-437165-5, pp. 99-113.		
/W.S./	A24	DAVIS, et al., "CpG DNA is a Potential Enhancer of Specific Immunity in Mice Immunized with Recombinant Hepatitis B Surface Antigen" <i>The American Association of Immunologists</i> , 1998, <i>The Journal of Immunology</i> , (1998), Vol. 160, pp. 870-876.		
/W.S./	A25	DAVISON, Andrew J., et al., "The Complete DNA Sequence of Varicella-Zoster Virus", J. gen. Virol., (1986), Vol. 67, pp. 1759-1816.		
/W.S./	A26	ERTL, C. J., et al., "Novel Vaccine Approaches", <i>The Journal of Immunology</i> , (1996), Vol. 156, pp. 3579-3582.		
/W.S./	A27	FYNAN, E. F., et al., "DNA Vaccines: Protective Immunizations by Parenteral, Mucosal, and Gene-Gun Inoculations", <i>Proc. Natl. Acad. Sci. USA</i> , December 1993, Vol. 90, pp. 11478-11482.		
/W.S./	A28	FYNAN, E. F., et al., "DNA Vaccines: A Novel Approach to Immunization", Int. J. Immunopharmac., (1995), Vol. 17, No. 2, pp. 79-83.		

Examiner Signature	/Wu-Cheng Winston Shen/	Date Considered	. 04/02/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

of the year of the reign of the Emperor must precede the serial number of the patent document, a kind of document by the appropriate symbols as included on the Cashadard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO INFORMATION DISCLOSURE				Complete if Known		
				Application Number	10/529,011	
	STATEMEN'	T BY APPL	ICANT	Filing Date	9/29/2003	
Date Submitted: February 20, 2007 (use as many sheets as necessary)				First Named Inventor	Ralph BRAUN	
				Art Unit	1632	
				Examiner Name	Shen, Wu Cheng Winston	
Sheet	3	of	4	Attorney Docket Number	036481-0165	-

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Till Itom (book magazino igurnal corial gumpoeium estelea eta) deta pagata) valuma igaua pumbor		
/W.S./	A29	HASSETT, D. E., et al., "DNA Immunization", <i>Trends in Microbiol.</i> , August 1996, Vol. 8, pp. 307-312.		
/W.S./	A30	HOUGHTON, Michael, et al., "Molecular Biology of the Hepatitis C Viruses: Implications for Diagnosis, Development and Control of Viral Disease", <i>Hepatology</i> , (1991), Vol. 14, No. 2, pp. 381-388.		
/W.S./	A31	IMOTO, M., et al., "Total Synthesis of Escherichia Coli Lipid A", Tetrahedron Letters, (1985), Vol. 26, No. 12, pp. 1545-1548.		
/W.S./	A32	KILPATRICK, K. E., et al., "Rapid Development of Affinity Matured Monoclonal Antibodies Using RIMMS", Hybridoma, (1997), Vol. 16, No. 4, pp. 381-389.		
/W.S./	A33	KILPATRICK, K. E., et al., "Gene Gun Delivered DNA-Based Immunizations Mediate Rapid Production of Murine Monoclonal Antibodies to the Flt-3 Receptor", of Murine Monoclonal Antibodies to the Flt-3 Receptor", <i>Hybridoma</i> , (1998), Vol. 17, No. 6, pp. 569-576.		
/W.S./	A34	KRIEG, A. M., et al., "CpG Motifs in Bacterial DNA Trigger Direct B-Cell Activation", Nature, April 6, 1005, Vol. 374, pp. 546-549.		
/W.S./	A35	LACHMANN, R. H., et al., "The Use of Herpes Simplex Virus-Based Vectors for Gene Delivery to the Nervous System", <i>Molecular Medicine Today</i> , September, (1997), Vol. 3, No. 9, pp. 404-411.		
/W.S./	A36	LATCHMAN, D. S., et al., "Gene Delivery and Gene Therapy with Herpes Simplex Virus-Based Vectors", <i>Gene</i> , (2001), Vol. 264, pp. 1-9.		
/W.S./	A37	MANICKAN, Elanchezhiyan, et al., "DNA Vaccines – A Modern Gimmick or a Boon to Vaccinology?", Critical Reviews in Immunology, (1997), Vol. 17, pp. 139-154.		
/W.S./	A38	MCGEOCH, D.J., et al., "The Complete DNA Sequence of the Long Unique Region in the Genome of Herpes Simplex Virus Type 1", <i>J. gen. Virol.</i> , (1988), Vol. 69, pp. 1531-1574.		
/W.S./	A39	MEDZHITOV, R., et al., "Innate Immunity: Impact on the Adaptive Immune Response", Current Opinion in Immunology, (1997), Vol. 9, pp. 4-9.	-	
/W.S./	A40	MODROW, S., "Computer-Assisted Analysis of Envelope Protein Sequences of Seven Human Immunodeficiency Virus Isolates: Prediction of Antigenic Epitopes in Conserved and Variable Regions", <i>Journal of Virology</i> , Feb. 1987, Vol. 61, No. 2, pp. 570-578.		

			
Examiner	My Chang Winston Chant	Date	1
Signature	/Wu-Cheng Winston Shen/	Considered	04/02/2007
			L

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is considered by 27 CEP 1.97 and 1.98. The information is considered to obtain a receipt by the public which is to file (and by the USPTO to

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number, Substitute for form 1449/PTO Complete if Known **Application Number** INFORMATION DISCLOSURE 10/529,011 STATEMENT BY APPLICANT Filing Date 9/29/2003 **First Named Inventor** Ralph BRAUN Date Submitted: February 20, 2007 Art Unit 1632

Examiner Name Shen, Wu Cheng Winston (use as many sheets as necessary) Attorney Docket Number Sheet 036481-0165

NON PATENT LITERATURE DOCUMENTS				
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		
/W.S./	A41	PAYNE, L. G., et al., "Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a Potent Immunoadjuvant for an Influenza Vaccine", <i>Vaccine</i> , (1998), Vol. 16, No. 1, pp. 92-98.		
/W.S./	A42	PERTMER, T. M., et al., "Gene Gun-Based Nucleic Acid Immunization: Elicitation of Humoral and Cytotoxic T Lymphocyte Responses Following Epidermal Delivery of Nanogram Quantities of DNA", Vaccine, (1995) Vo. 13, No. 15, pp. 1427-1430.		
/W.S./	A43	RAZ, E., et al., "Intradermal Gene Immunization: The Possible Role of DNA Uptake in the Induction of Cellular Immunity to Viruses", <i>Proc. Natl. Acad. Sci, USA</i> , September 1994, Vol. 91, pp. 9519-9523.		
/W.S./	A44	THOMAS, S. K., "Herpes Simplex Virus Latency-Associated Transcript Encodes a Protein Which Greatly Enhances Virus Growth, Can Compensate for Deficiencies in Immediate-Early Gene Expression, and is Likely to Function During Reactivation from Virus Latency", <i>Journal of Virology</i> , August 1999, Vol. 73, No. 8, pp. 6618-6625.		
/W.S./	A45	WOLFF, J. A., "Direct Gene Transfer into Mouse Muscle in Vivo", <i>Science</i> , March 23, 1990, Vol. 247, pp. 1465-1468.		
/W.S./	A46	YANG, N-S, et al., "In vivo and in vitro Gene Transfer to Mammalian Somatic Cells by Particle Bombardment", Proc. Natl. Acad. Sci. USA, December 1990, Vol. 87, pp. 9568-9572.		

Examiner Signature	/Wu-Cheng Winston Shen/	Date Considered	04/02/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to

process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.